ABAXIS (ABAX) Shares are Down -13.93%

ABAXIS (ABAX) has risen sharply, recording gains of 3.6% in the past 4 weeks. However, the stock has corrected -13.93% in the past 1 week, providing a good buying opportunity on dips. ABAXIS (ABAX) : During the past 4 weeks, traders have been relatively bearish on ABAXIS (ABAX), hence the stock is down -2.96% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -14.45% relative to the S&P 500.

ABAXIS (NASDAQ:ABAX): The stock opened at $49.50 on Friday but the bulls could not build on the opening and the stock topped out at $49.50 for the day. The stock traded down to $46.02 during the day, due to lack of any buying support eventually closed down at $46.36 with a loss of -15.32% for the day. The stock had closed at $54.75 on the previous day. The total traded volume was 1,097,571 shares.


The stock has recorded a 20-day Moving Average of 7.16% and the 50-Day Moving Average is 1.69%. Abaxis, Inc. is up 0.07% in the last 3-month period. Year-to-Date the stock performance stands at -16.29%.

Abaxis, Inc. is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company operates through the two segments: the medical market and the veterinary market. The Companys medical market customer group consists of physicians office practices across multiple specialties, urgent care, outpatient and walk-in clinics, health screening operations, home care providers and nursing homes. The Companys medical market products include: Piccolo chemistry analyzers and consumable products. The Companys veterinary market product offerings include VetScan chemistry analyzers and veterinary reagent discs, VetScan hematology instruments and related reagent kits, VetScan VSpro specialty analyzers and related consumables, VetScan i-STAT analyzers and related consumables and VetScan rapid tests.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.